ClinicalTrials.gg
CompletedNCT02196077PT009001Updated Jun 20, 2018Results posted

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of BFF MDI 320/9.6 μg and BFF MDI 160/9.6 μg in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 17 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-20.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 43
180 · median 99
Started
2014
with 3 others
Phase 2
2 of 43
none open now
Registered
20th of 43
by date
Lead sponsor
7 of 43
Pearl Therapeutics, Inc.

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 4 that started in 2014, is one of 2 in phase 2, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD. The overall objective is to demonstrate that the combination of budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009) provides benefit on lung function compared with BD MDI in subjects with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Budesonide and formoterol inhalation aerosol
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Form (ICF) prior to any study related procedures
  • Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
  • Tobacco Use: Current or former smokers with a history of at least 10 pack years of cigarette smoking
  • Women of non- or medically acceptable for women of child-bearing potential and males with female partners of childbearing potential
  • Severity of Disease: Subjects with an established clinical history of COPD and severity defined as: /forced vital capacity (FVC) ratio of \<0.70; At Screening (Visit 1a/b), post bronchodilator FEV1 must be \<80% predicted normal value, calculated using NHANES III (Third National Health and Nutrition Examination Survey) reference equations; the measured FEV1 must also be ≥30% of predicted normal value; at Visit 2, the average of the 60 minutes and 30 minutes pre dose FEV1 assessments must be \<80% predicted normal value calculated using NHANES III reference equations
  • Screening clinical laboratory tests must be acceptable to the Investigator
  • Screening must be acceptable to the Investigator
  • Chest x ray or computerized tomography (CT) scan within 6 months prior to Visit 1a must be acceptable to the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Significant diseases other than , ie., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
  • Pregnancy, nursing female subjects, or subjects trying to conceive, or not using medically acceptable form of
  • Asthma: Subjects who have a primary diagnosis of asthma (Note: Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis).
  • Alpha 1 Antitrypsin Deficiency: Subjects who have alpha 1 antitrypsin deficiency as the cause of COPD -Active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea (ie., in the opinion of the Investigator severity of the disorder would impact the conduct of the study)-
  • neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
  • Poorly Controlled COPD
  • History of abnormalities
  • Cancer not in complete remission for at least 5 years
  • Clinically significant, symptomatic prostatic hypertrophy
  • Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
  • Clinically significant bladder neck obstruction or urinary retention
  • Inadequately treated glaucoma
  • History of an allergic reaction or to any drug or to any component of the formulations used in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    BFF MDI 320/9.6 μg

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

    Drug: BFF MDI 320/9.6 μg

  • Experimental
    BFF MDI 160/9.6 μg

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

    Drug: BFF MDI 160/9.6 μg

  • Experimental
    BFF MDI 80/9.6 μg

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

    Drug: BFF MDI 80/9.6 μg

  • Experimental
    BD MDI 320 μg

    Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)

    Drug: BD MDI 320 μg

  • Experimental
    FF MDI 9.6 μg

    Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)

    Drug: FF MDI 9.6 μg

Interventions

  • DrugBFF MDI 320/9.6 μg

    Drug pages: Budesonide · Formoterol

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • DrugBFF MDI 160/9.6 μg

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • DrugBFF MDI 80/9.6 μg

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • DrugBD MDI 320 μg

    Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)

  • DrugFF MDI 9.6 μg

    Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)

06

What researchers measure

Primary outcomes

  1. FEV1 AUC0-12 on Day 29

    Change from Baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12)

    Time frame: Day 29

Secondary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days

    Time frame: Over 28 days

  2. Peak Change From Baseline in FEV1 (in Liters) Day 15

    Time frame: Day 15

  3. Peak Change From Baseline in FEV1 (in Liters) Day 29

    Time frame: Day 29

  4. Peak Change From Baseline in FEV1 on Day 1

    Time frame: Day 1

  5. Forced Vital Capacity (FVC) AUC0-12 on Day 29

    Time frame: Day 29

  6. Transition Dyspnea Index (TDI) Focal Score on Day 29

    Min/Max Range of TDI scale -9 (major deterioration) to +9 (major improvement)

    Time frame: Day 29

  7. Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment

    Time frame: Visit 12-13 (7 days)

07

Results

Posted May 9, 2017

Participant flow

This study was conducted at 20 sites in the United States from August 2014 to March 2015. Study participation was a maximum of 28 days.

Participant flow — Overall Study
MilestoneSubjects
Started180
Bff mdi 320/9.6 μg155
Bff mdi 160/9.6 μg106
Bff mdi 80/9.6 μg103
Bd mdi 320 μg108
Ff mdi 9.6 μg157
Completed133
Not completed47
Withdrew: Adverse event4
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject14
Withdrew: Physician decision1
Withdrew: Lost to follow-up3
Withdrew: Protocol violation24

Outcome measures

PrimaryFEV1 AUC0-12 on Day 29

Change from Baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12)

Time frame:
Day 29
Reported as:
Least squares mean · Liters
FEV1 AUC0-12 on Day 29
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
FEV1 AUC0-12 on Day 290.231 (0.197 to 0.266)0.197 (0.158 to 0.236)0.205 (0.165 to 0.244)0.011 (-0.028 to 0.050)0.176 (0.141 to 0.210)
SecondaryChange From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days
Time frame:
Over 28 days
Reported as:
Least squares mean · Liters
Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days0.138 (0.111 to 0.165)0.121 (0.089 to 0.153)0.110 (0.078 to 0.142)0.022 (-0.009 to 0.054)0.083 (0.056 to 0.110)
SecondaryPeak Change From Baseline in FEV1 (in Liters) Day 15
Time frame:
Day 15
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 (in Liters) Day 15
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Peak Change From Baseline in FEV1 (in Liters) Day 150.388 (0.354 to 0.422)0.366 (0.327 to 0.405)0.348 (0.308 to 0.387)0.143 (0.104 to 0.182)0.320 (0.286 to 0.354)
SecondaryPeak Change From Baseline in FEV1 (in Liters) Day 29
Time frame:
Day 29
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 (in Liters) Day 29
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Peak Change From Baseline in FEV1 (in Liters) Day 290.390 (0.356 to 0.424)0.356 (0.317 to 0.395)0.359 (0.319 to 0.398)0.138 (0.099 to 0.177)0.322 (0.287 to 0.356)
SecondaryPeak Change From Baseline in FEV1 on Day 1
Time frame:
Day 1
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 on Day 1
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Peak Change From Baseline in FEV1 on Day 10.338 (0.304 to 0.372)0.310 (0.271 to 0.349)0.314 (0.275 to 0.354)0.096 (0.058 to 0.135)0.313 (0.279 to 0.347)
SecondaryForced Vital Capacity (FVC) AUC0-12 on Day 29
Time frame:
Day 29
Reported as:
Least squares mean · Liters
Forced Vital Capacity (FVC) AUC0-12 on Day 29
LitersBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Forced Vital Capacity (FVC) AUC0-12 on Day 290.305 (0.244 to 0.365)0.245 (0.176 to 0.315)0.267 (0.196 to 0.337)0.002 (-0.068 to 0.071)0.253 (0.191 to 0.314)
SecondaryTransition Dyspnea Index (TDI) Focal Score on Day 29

Min/Max Range of TDI scale -9 (major deterioration) to +9 (major improvement)

Time frame:
Day 29
Reported as:
Least squares mean · Index
Transition Dyspnea Index (TDI) Focal Score on Day 29
IndexBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Transition Dyspnea Index (TDI) Focal Score on Day 290.598 (0.298 to 0.899)0.882 (0.518 to 1.246)0.459 (0.093 to 0.825)-0.109 (-0.468 to 0.250)0.260 (-0.047 to 0.566)
SecondaryChange From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment
Time frame:
Visit 12-13 (7 days)
Reported as:
Least squares mean · Puffs
Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment
PuffsBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment0.05 (-0.34 to 0.43)0.16 (-0.27 to 0.58)0.24 (-0.19 to 0.67)0.96 (0.54 to 1.38)0.44 (0.06 to 0.83)

Adverse events

Collected over AEs were recorded from the time subjects received their first dose of study medication, during the entire study period, and up to 14 days from the date of the last study medication dose.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BFF MDI 320/9.6 ug—4/155 (2.6%)12/155 (7.7%)
BFF MDI 160/9.6 ug—2/106 (1.9%)2/106 (1.9%)
BFF MDI 80/9.6 ug—3/103 (2.9%)5/103 (4.9%)
BD MDI 320 ug—4/108 (3.7%)8/108 (7.4%)
FF MDI 9.6 ug—2/157 (1.3%)8/157 (5.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/1550/1061/1032/1080/157
Acute Myocardial InfarctionCardiac disorders0/1550/1061/1030/1080/157
Angina PectorisCardiac disorders0/1550/1061/1030/1080/157
Cerebrovascular AccidentNervous system disorders0/1550/1061/1030/1080/157
Back PainMusculoskeletal and connective tissue disorders0/1551/1060/1030/1080/157
Small Intestinal ObstructionGastrointestinal disorders0/1551/1060/1030/1080/157
Clostridium Difficile ColitisInfections and infestations0/1550/1060/1031/1080/157
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1550/1060/1031/1080/157
OsteoarthritisMusculoskeletal and connective tissue disorders0/1550/1060/1031/1080/157
Laryngeal OedemaRespiratory, thoracic and mediastinal disorders1/1550/1060/1030/1080/157
Most frequent other events
Most frequent other events
EventBFF MDI 320/9.6 ugBFF MDI 160/9.6 ugBFF MDI 80/9.6 ugBD MDI 320 ugFF MDI 9.6 ug
NasopharyngitisInfections and infestations5/1551/1062/1032/1085/157
HypertensionCardiac disorders2/1551/1061/1033/1082/157
CoughRespiratory, thoracic and mediastinal disorders1/1550/1061/1033/1081/157
Upper Respiratory Tract InfectionInfections and infestations4/1550/1061/1030/1080/157

Baseline characteristics

The ITT population used in participant flow, Population is defined as all subjects who were randomized to treatment and received at least one dose of BFF MDI 320/9.6 ug, BFF MDI 160/9.6 ug, BFF MDI 80/9.6 ug, BD MDI 320 ug or FF MDI 9.6 ug. Statistical tabulations and analyses will be by randomized treatment.

Age, Continuous
Age, Continuous(Years)Subjects
Mean62.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Subjects
Female96
Male84
08

Study locations

17 sites
  • Pearl Investigative Site
    Rolling Hills Estates, California, United States
  • Pearl Investigative Site
    Clearwater, Florida, United States
  • Pearl Investigative Site
    Panama City, Florida, United States
  • Pearl Investigative Site
    Tampa, Florida, United States
  • Pearl Investigative Site
    Winter Park, Florida, United States
  • Pearl Investigative Site
    Edina, Minnesota, United States
  • Pearl Investigative Site
    Minneapolis, Minnesota, United States
  • Pearl Investigative Site
    Woodbury, Minnesota, United States
  • Pearl Investigative Site
    Saint Charles, Missouri, United States
  • Pearl Investigative Site
    Charlotte, North Carolina, United States
  • Pearl Investigative Site
    Cincinnati, Ohio, United States
  • Pearl Investigative Site
    Columbus, Ohio, United States
  • Pearl Investigative Site
    Dublin, Ohio, United States
  • Pearl Investigative Site
    Medford, Oregon, United States
  • Pearl Investigative Site
    Easley, South Carolina, United States
  • Pearl Investigative Site
    Greenville, South Carolina, United States
  • Pearl Investigative Site
    Spartanburg, South Carolina, United States
09

References and documents

Related links

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Mar 2015, 7 months.

Results were first posted in May 2017, 2 years 2 months after primary completion. A results delay was requested in Feb 2016.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2014
First posted
Jul 21, 2014
StartActual
Aug 1, 2014
Primary completionActual
Mar 1, 2015
CompletionActual
Mar 1, 2015
Results delay requested
Feb 16, 2016
Results first posted
May 9, 2017
Last update
Jun 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02196077
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Aug 1, 2014
Primary completion
Mar 1, 2015
Completion
Mar 1, 2015
Results posted
May 9, 2017
Last update
Jun 20, 2018

Study contacts

Shahid Siddiqui, MD, MHSA
study director · Pearl Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion